Sprouts Farmers Market closes $600 million revolving credit facility
DEERFIELD, IL – Baxter International Inc. (NYSE:BAX), a $16.6 billion healthcare equipment company with a "Good" financial health rating according to InvestingPro, has finalized the sale of various subsidiaries to Spruce Bidco entities for an adjusted cash sum of approximately $3.71 billion, the healthcare company disclosed in a recent SEC filing.
The transaction, which was completed on Monday, involved the divestiture of its renal care businesses, including Vantive Health and Gambro Renal Products. The company, which has maintained dividend payments for 54 consecutive years, currently trades below its Fair Value based on comprehensive analysis.
The sale aligns with an agreement dated August 12, 2024, and includes Baxter’s equity interests in several U.S. and international corporations. The initial agreement stipulated a purchase price of $3.80 billion, with the final amount subject to customary adjustments for cash, working capital, and debt. Post-closing adjustments may still affect the net proceeds. With trailing twelve-month revenue of $15.1 billion and an EBITDA of $2.8 billion, this transaction represents a significant portion of Baxter’s operations.
As part of the deal, effective Monday, certain equity and cash-based retention awards for Vantive Transferred Business Employees vested pro rata, and Spruce Bidco is obligated to grant replacement cash-based awards for the forfeited portion of these awards, excluding underwater stock options.
Concurrently with the asset disposition, Chris Toth, Executive Vice President and Group President, Kidney Care, has stepped down from his executive role at Baxter. Toth is entitled to pro rata vesting treatment of his outstanding and unvested long-term incentive plan (LTIP) awards as per the terms of the sale.
The completion of this divestiture marks a significant restructuring for Baxter, as it sheds its renal care segment to focus on its core healthcare businesses. The company’s SEC filing and the first amendment to the Equity Purchase Agreement provide detailed information on the transaction.
For investors seeking deeper insights, InvestingPro offers exclusive analysis through its comprehensive Pro Research Report, one of 1,400+ available for top US stocks, revealing detailed metrics and expert analysis that could help evaluate the impact of this strategic move. Baxter’s shares are traded on the New York Stock Exchange and the transaction is expected to have immediate financial implications for the company.
This news article is based on a press release statement.
In other recent news, Baxter International Inc. reported a 4% increase in sales year-over-year in Q3 2024, reaching $3.85 billion, with adjusted earnings per share (EPS) of $0.80, surpassing their guidance. Despite a projected $200 million sales decrease in Q4 due to Hurricane Helene, Baxter forecasts 1% to 2% full-year 2024 sales growth and an adjusted EPS of $2.90 to $2.94. The company also announced the appointment of Ms. Anita Zielinski as Senior Vice President, Chief Accounting Officer, and Controller, and the planned sale of their Kidney Care business to Carlyle, expected to close in late 2024 or early 2025.
Changes in Baxter’s board were also announced, with Mr. Peter M. Wilver resigning from the Board of Directors and Mr. Jeffrey A. Craig assuming the position of chairperson of the Audit Committee. Baxter’s financial health score, as analyzed by InvestingPro, indicates a strong position in the Healthcare Equipment & Supplies industry. The company’s net income is expected to grow this year, despite analysts anticipating a sales decline.
These recent developments reflect Baxter’s commitment to strong leadership and governance within its financial operations. Baxter’s executive team remains optimistic about the company’s future, with a strong emphasis on growth through innovation and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.